| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
IM Cannabis Corp. Common Shares
$3.06
-1.09 (-26.33%)
Market Cap
1.87 M
EPS
-1.48
P/E Ratio
-
Value Trade
80.91 K
80.98 %
Week
2,594.06 %
1 Month
1,740.3 %
3 Month
395.8 %
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
26.34 M
52 Week Range
0.09 - 8.65
% held by Insiders
11.78 %
% held by Institutions
11.69 %
Enterprise Value
11.78 M
Total Shares
603.92 K
Short %
13.93 %
Float Shares
90.00 K
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for IM Cannabis Corp. Common Shares
221Total events
3Upcoming
58Tier-1 (high impact)
2021 – 2026Coverage
Upcoming catalysts 2
TBD
T1Acquisition
Subscribe to view catalyst details
TBD
T2Reverse Stock Split
Subscribe to view catalyst details
Event history 2
TBD
●Reverse Stock SplitCorporate
Subscribe to view catalyst details
TBD
▼Reverse Stock SplitCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
No drug pipeline
IM Cannabis Corp. Common Shares is not a drug developer. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
INSIDER TRANSACTIONSMonthly totals, since 2023
BuysSellsStock price
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in IMCC
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
IMCC Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-IMCC
Sep 23, 2026▼ -26.3%today
IM Cannabis Announces Pricing of US$1.31 Million Registered Direct Offering of Common Shares
IM Cannabis Corp. announced a registered direct offering of 655,000 common shares at US$2.00 per share, aiming to raise approximately US$1.31 million. The proceeds will be utilized for working capital and evaluating new business opportunities. The offering is subject to customary closing conditions and may involve related party transactions.
Read more →-IMCC
Sep 23, 2026▼ -26.3%today
IM Cannabis Enters Non-Binding Agreement to Acquire 51% of Space Defense Innovations, Operating in the European Tactical UAS Market
IM Cannabis Corp. has signed a non-binding Letter of Intent to acquire 51% of Space Defense Innovations LLC, which operates in the European unmanned aerial systems market. This move aims to diversify IMCC's business beyond its core medical cannabis operations. The acquisition includes a combination of shares and warrants, with a five-year option to acquire additional shares. However, the deal is contingent on several regulatory and corporate approvals.
Read more →-IMCC
Aug 27, 2026▼ -13.5%on this news· ran to -24% by day 3
IM Cannabis Shares Commence Trading on 30:1 Consolidated Basis
IM Cannabis Corp. has begun trading its common shares on a 30:1 consolidated basis on the Nasdaq. The company aims to improve its share price and maintain compliance with Nasdaq's listing requirements. Shareholders will receive instructions for exchanging their pre-consolidation shares. The company operates in Israel and Germany, focusing on medical cannabis.
Read more →-IMCC
Aug 18, 2026IM Cannabis Announces Intention to Complete 30:1 Share Consolidation to Support Nasdaq Minimum Bid Price Compliance
IM Cannabis Corp. has announced a 30:1 share consolidation approved by its board to comply with Nasdaq's minimum bid price requirement. The consolidation is expected to take effect on August 27, 2026, with shares trading on a post-consolidation basis. The company aims to increase its share price to regain compliance by the October 6, 2026 deadline.
Read more →-IMCC
Aug 17, 2026▼ -14%on this newsshared move
IM Cannabis Enters into Agreement to Sell IMC Holdings and European- Focused Assets
IM Cannabis Corp. has entered into a definitive share purchase agreement to sell IMC Holdings and its European-focused assets to Slil.com Holding Ltd. The transaction is expected to enhance shareholders' equity by approximately CAD$3 million and streamline the company's operations. However, it is classified as a related party transaction due to the CEO's involvement, raising potential concerns about conflicts of interest.
Read more →-IMCC
Aug 13, 2026▼ -6.1%on this news· ran to -19% by day 1shared move
IM Cannabis Corp. Announces Second Quarter and First Half 2026 Financial Results
IM Cannabis Corp. reported its financial results for Q2 and the first half of 2026, showing a significant decline in revenue and an increase in losses compared to the same periods in 2025. Revenue for the first half was $16.3 million, down from $25.2 million, while the net loss reached $6.9 million. The company's cash reserves also fell, raising concerns about financial stability.
Read more →-IMCC
Aug 7, 2026IM Cannabis Raises US$250,000 of Gross Proceeds in Convertible Note Financing
IM Cannabis Corp. has successfully closed a US$250,000 convertible note financing with an institutional investor. The financing includes an 8% interest note convertible into common shares at a set price or a percentage of market value. The company plans to use the proceeds for general corporate purposes while managing risks associated with regulatory compliance and market competition.
Read more →-IMCC
Jul 27, 2026IM Cannabis Provides Corporate Update
IM Cannabis Corp. has announced the resignation of Mr. Alon Dayan from its board of directors for personal reasons. The company expressed appreciation for his contributions during his tenure. IM Cannabis continues to focus on expanding its medical cannabis operations in Israel and Germany, while exploring new technology-driven opportunities.
Read more →-IMCC
Jun 18, 2026▼ -16.5%on this news
IM Cannabis Corp. Enters into Letter of Intent to Sell its European Activities, Expects to Significantly Reduce Debt by CAD$10.5 million
IM Cannabis Corp. has entered a non-binding letter of intent to sell its European operations to Slil.com Holding Ltd., which will significantly reduce the company's debt by CAD$10.5 million. The transaction allows IMC to concentrate on its Israeli market while pursuing new investment opportunities. The deal is subject to further negotiations and regulatory approvals.
Read more →-IMCC
Jun 9, 2026▼ -14.5%on this news
IM Cannabis Announces Form F-3 Resale Registration Statement Filing
IM Cannabis Corp. has announced the filing of a resale registration statement on Form F-3 with the SEC for 17,276,931 common shares. This registration includes shares from several convertible promissory notes, emphasizing the company's focus on managing its financial operations. While the statement has potential benefits for liquidity, it has not yet been made effective by the SEC, introducing an element of uncertainty. The company continues to operate in the medical cannabis market primarily in Israel and Germany.
Read more →-IMCC
Jun 3, 2026IM Cannabis Raises US$225,000 of Gross Proceeds in Convertible Note Financing
IM Cannabis Corp. has finalized a convertible note financing deal, raising US$225,000 from an institutional investor. The financing terms include an interest rate of 8% per annum, potentially increasing to 14% upon an event of default. The proceeds are aimed at funding general corporate activities, helping the company bolster its operations in the medical cannabis sector. Furthermore, the company will issue warrants as part of this financing deal, indicating an effort to provide future growth and investor confidence.
Read more →-IMCC
May 13, 2026IM Cannabis Corp. Announces First Quarter 2026 Financial ResultsUSA - EnglishIsrael - English
IM Cannabis Corp. announced its financial results for Q1 2026, reporting revenues of $8.7 million but a net loss of $2.5 million. The company has made strides in cost optimization, reducing administrative expenses by 22% year-over-year. Management is focused on operational efficiencies and exploring strategic growth opportunities despite facing inherent risks in the cannabis industry.
Read more →-IMCC
May 7, 2026IM Cannabis Raised US$550,000 of Gross Proceeds in Convertible Note Financings
IM Cannabis Corp. has successfully closed a US$300,000 convertible note financing, adding to a total of US$550,000 raised in recent financings. The funds will be utilized for general corporate purposes. The company operates in Israel and Germany, focusing on medical cannabis distribution and retail. However, it faces regulatory and market challenges that could impact its future growth.
Read more →-IMCC
Apr 10, 2026IMC Announces Receipt of Nasdaq Minimum Bid Price Notification
IM Cannabis Corp. (IMC) has received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement of $1.00 per share. The company has 180 days to regain compliance, during which its shares will continue to trade. If compliance is not achieved, IMC may qualify for an additional compliance period but risks delisting if it fails to meet requirements.
Read more →-IMCC
Mar 31, 2026▼ -9.3%on this news· ran to -25% by day 1
IM Cannabis Reports 2025 Results: Revenue of C$54.7 Million with Over 134% Growth in Germany and Positive Operating Cash FlowUSA - EnglishIsrael - English
IM Cannabis Corp. reported a significant operational turnaround in 2025, achieving positive cash flow of C$4.7 million and over 134% revenue growth in Germany. The company is diversifying its business by planning to acquire a 51% stake in Black Axe Technologies, which specializes in defense technology. Despite these achievements, IMC faces regulatory and geopolitical risks that could impact its future operations.
Read more →-IMCC
Mar 17, 2026▼ -19.4%on this news
IMC Announces a Strategic Entry to the Cyber Drone Interception and Satellite Intelligence Markets by Signing a Non-Binding Agreement to Acquire 51% of Blackaxe TechnologiesUSA - EnglishIsrael - English
IM Cannabis Corp. (IMC) has announced a non-binding agreement to acquire 51% of Blackaxe Technologies, a Polish firm specializing in defense and intelligence solutions. This move marks IMC's strategic entry into the defense sector, addressing the rising demand for satellite intelligence and counter-drone technologies amid global geopolitical tensions. The transaction is contingent upon due diligence and regulatory approvals.
Read more →-IMCC
Jan 26, 2026IM Cannabis Raises US$2,171,660.40 in Note Purchase AgreementsUSA - EnglishIsrael - English
IM Cannabis Corp. has raised US$2,171,660.40 through two note purchase agreements to address liquidity needs. The financing includes two notes with varying principal amounts and interest rates, both convertible into common shares. A portion of the proceeds will be used to repay creditors, enhancing the company's financial position while also funding operational initiatives.
Read more →-IMCC
Jan 5, 2026IM Cannabis Announces the Appointment of Mr. Alon Dayan to its Board of DirectorsUSA - EnglishIsrael - English
IM Cannabis Corp. has appointed Mr. Alon Dayan to its board of directors, effective December 31, 2025. Mr. Dayan, currently the CEO of KeepZone AI Inc., has over 15 years of experience in the homeland security technology sector. His background includes founding and scaling companies focused on secure communications and international business development.
Read more →-IMCC
Dec 30, 2025IM Cannabis Explores U.S. Market Entry Following President Trump's Executive Order on Increasing Medical Marijuana and Cannabidiol ResearchUSA - EnglishIsrael - English
IM Cannabis Corp. is evaluating opportunities to enter the U.S. cannabis market following President Trump's executive order aimed at rescheduling marijuana. The company has engaged SSC Advisors to assist in this strategic initiative and to explore potential divestitures of its operations in Germany and Israel. IMC aims to leverage its experience in international medical cannabis to capitalize on new market opportunities.
Read more →-IMCC
Dec 12, 2025▲ +12.6%on this news
IM Cannabis Appoints Asi Levi as Chief Financial Officer
IM Cannabis Corp. has appointed Asi Levi as its new Chief Financial Officer, effective immediately, replacing Uri Birenberg. Levi comes with over 15 years of financial expertise, having held CFO positions at various companies and overseen significant financial operations. This leadership change is part of IMC's strategy to strengthen its financial management as it continues to focus on growth in medical cannabis markets in Israel and Germany.
Read more →-IMCC
Nov 13, 2025▼ -9%on this news
IM Cannabis Reports Third Quarter 2025 Financial ResultsUSA - EnglishIsrael - English
IM Cannabis Corp. reported its financial results for Q3 2025, highlighting a transition year impacted by potential regulatory changes in Germany. The company recorded a non-cash impairment and is assessing new business opportunities for growth. Concerns about its ability to continue as a going concern were also noted in the financial statements.
Read more →-IMCC
Nov 6, 2025IM Cannabis to Report third Quarter 2025 Financial Results on Thursday, November 13th at 9:00am ETUSA - EnglishIsrael - English
IM Cannabis Corp. will announce its third quarter 2025 financial results on November 13, 2025. The report will cover operational and financial performance for the period ending September 30, 2025. IMC operates in Israel and Germany, focusing on premium medical cannabis products and sustainable growth. The company aims to enhance its market presence through a data-driven approach.
Read more →-IMCC
Oct 23, 2025IM Cannabis Signs Non-Binding Term Sheet to Acquire 60% Stake in Innovative Quantum Computing Bio Data Company for Up to $54 MillionUSA - EnglishIsrael - English
IM Cannabis Corp. has signed a non-binding term sheet to acquire a 60% stake in a quantum computing bio data company for up to $54 million. This strategic move aims to enhance the company's growth and shareholder value by leveraging innovative technologies in biological data processing. However, the deal is contingent on due diligence and regulatory approvals, with no assurance of completion.
Read more →-IMCC
Sep 16, 2025IM Cannabis Announces Board Changes and Strategic Decision to Identify Additional Business OpportunitiesUSA - EnglishIsrael - English
IM Cannabis Corp. has announced changes to its Board of Directors, with the resignation of Shmulik Arbel and Brian Schinderle. New members Asaf Yitzhaik and Eli Zamir have been appointed to fill these vacancies. The company is also exploring additional business opportunities to enhance growth and shareholder value.
Read more →-IMCC
Sep 5, 2025IM Cannabis Regains Compliance with Nasdaq Stockholders' Equity Listing RequirementUSA - EnglishIsrael - English
IM Cannabis Corp. has announced that it has regained compliance with Nasdaq's stockholders' equity listing requirement, allowing its common stock to continue trading on the Nasdaq Capital Market. The company operates in Israel and Germany, providing medical cannabis products while adhering to strict regulatory standards. Despite this positive development, IM Cannabis faces various risks, including regulatory compliance and market competition.
Read more →-IMCC
Aug 13, 2025IM Cannabis Announces Warrant Amendments and Form F-3 Resale Registration Statement FilingUSA - EnglishIsrael - English
IM Cannabis Corp. has announced amendments to its November 2024 Warrants, reducing the exercise price from C$4.32 to C$3.43 and extending the expiration date to July 31, 2030. Additionally, the company filed a Form F-3 Resale Registration Statement with the SEC, registering nearly 5 million common shares. The transaction involved related party participation, which has raised some regulatory considerations.
Read more →-IMCC
Aug 12, 2025▼ -11.3%on this newsshared move
IM Cannabis Reports Second Quarter 2025 Financial Results
IM Cannabis Corp. (IMCC) reported its financial results for Q2 2025, highlighting a significant increase in gross profit and margin despite a decrease in revenue. The company experienced a 14% decline in revenue due to challenges related to the ongoing conflict in Israel and supply chain issues. However, IMC achieved a gross profit of $3.4 million, a 306% increase from the previous year, alongside a return to EBITDA profitability. Management is optimistic about recovery and sustainable growth moving forward.
Read more →-IMCC
Aug 4, 2025IM Cannabis to Report Second Quarter 2025 Financial Results on Tuesday, August 12th at 9:00am ET
IM Cannabis Corp. (NASDAQ: IMCC) announced that it will report its financial results for the second quarter of 2025 on August 12, 2025, prior to market opening. The company continues to operate in the medical cannabis sectors of Israel and Germany, focusing on premium cannabis products. IMC aims for sustainable growth while maintaining compliance with regulatory standards and harnessing a unique global supply chain.
Read more →-IMCC
Jul 31, 2025IM Cannabis Closes Private Placement for Gross Proceeds of Approximately US$4.1 Million
IM Cannabis Corp. has successfully completed a private placement of 2,050,000 units, raising approximately US$4.1 million. The funds will be used for working capital and to repay existing debts. Each unit includes common shares and warrants, with specific terms outlined for their exercise. The offering is exempt from certain registration requirements under U.S. securities law, allowing for a limited timeframe for resale registration.
Read more →-IMCC
Jul 11, 2025▼ -15.4%on this news
IM CANNABIS ANNOUNCES FILING OF SHELF REGISTRATION STATEMENT ON FORM F-3
IM Cannabis Corp. has announced the filing of a shelf registration statement on Form F-3 with the SEC, enabling it to offer and sell up to $50 million in common shares and other securities. This allows flexibility in financing options to meet capital needs while complying with market conditions. The company emphasizes its commitment to responsible growth and operations in the medical cannabis sectors of Israel and Germany. The registration does not guarantee a specific amount of securities will be sold, as it is subject to market demand and timing.
Read more →-IMCC
Jul 9, 2025▲ +5.5%on this newsshared move
IM Cannabis Announces the Signing of a Loan Agreement and Appointment of Oz Adler to Board of Directors
IM Cannabis Corp. has announced the appointment of Oz Adler to its board of directors alongside a loan agreement with L.I.A. Pure Capital Ltd., providing the Company with USD 1 million initially, with the possibility of an additional USD 1 million. Adler's background in finance and compliance is expected to support IMC's growth strategy. The loan has specific repayment terms and conditions, including a high interest rate and acceleration rights for the lender. The Company is also aiming to raise at least USD 3 million within 60 days to enhance its capital position.
Read more →-IMCC
Jul 1, 2025▲ +8.9%on this news· ran to +33% by day 3
IM Cannabis Provides Corporate Updates
IM Cannabis Corp. announced updates regarding its compliance status with Nasdaq listing requirements. The company received a deficiency letter indicating noncompliance with certain stockholders' equity rules, prompting it to submit a Compliance Plan. Nasdaq has granted the company an extension until October 6, 2025, to regain compliance. Despite current noncompliance, IMC's shares will continue to trade on Nasdaq while the company explores necessary measures to meet the requirements.
Read more →-IMCC
May 28, 2025▲ +44.9%on this news· ran to +167% by day 1
IM Cannabis Announces Plans to Voluntarily Delist from the Canadian Securities Exchange
IM Cannabis Corp. has announced its application for a voluntary delisting from the Canadian Securities Exchange (CSE), effective June 2, 2025, while continuing to trade on NASDAQ. The decision stems from the company’s assessment that the CSE listing incurs unnecessary costs and administrative burdens without justifying the trading volume. IM Cannabis aims to create a centralized marketplace on NASDAQ, which they believe will enhance shareholder value and simplify operations. The company expressed gratitude to the CSE for its initial support in accessing public markets.
Read more →-IMCC
May 15, 2025▲ +7.4%on this news
IM Cannabis Reports First Quarter Financial Results
IM Cannabis Corp. reported its financial results for Q1 2025, revealing a net profit of $0.2 million compared to a net loss of $6 million in Q1 2024. The company achieved a 94% increase in gross profit year-over-year, demonstrating significant operational improvements and a reduction in operating expenses. However, the revenue decline in Israel raises some concerns, although overall revenue in Q1 2025 reached $12.5 million, up from $12.1 million in Q1 2024. IMC also plans a private placement of secured convertible debentures to support future growth.
Read more →-IMCC
May 7, 2025▼ -5.7%on this news
IM Cannabis Announces Filing of Information Circular for Upcoming Annual General and Special Meeting and Provides Additional Information on the Focus Transaction
IM Cannabis Corp. has announced the filing of a management information circular for its upcoming annual general and special meeting set for May 23, 2025. The circular includes details on the proposed Focus Transaction, which is valued at approximately NIS 3.1 million based on future cash flows. The Company aims to settle the Focus Purchase Price through the issuance of Common Shares, pending shareholder approval. The announcement highlights the Company's commitment to transparency and compliance as it navigates its operations in the cannabis market.
Read more →-IMCC
May 6, 2025▲ +11.4%on this newsshared move
IM Cannabis to Report First Quarter 2025 Financial Results on Thursday, May 15th at 9:00am ET
IM Cannabis Corp. will report its financial results for the first quarter of 2025 on May 15, 2025. The company, which operates in Israel and Germany, will conduct a web conference at 9:00 AM ET to discuss its performance and answer investor questions. This event emphasizes IMC's commitment to transparency and investor relations as they navigate the medical cannabis market.
Read more →-IMCC
Mar 31, 2025▼ -17.9%on this news
IM Cannabis Reports Fourth Quarter and Full Year 2024 Financial Results
IM Cannabis Corp. reported its fourth quarter and full year 2024 financial results, showcasing significant growth and improvements. The company achieved a 25% revenue increase in Q4 and a $0.5M Adjusted EBITDA profit, marking a substantial recovery from losses in the previous year. Additionally, operational efficiencies led to a 42% reduction in operating expenses. However, the cancellation of the Oranim agreement impacted revenue, and the company reported a net loss increase, raising questions about its ability to continue as a going concern.
Read more →-IMCC
Mar 20, 2025▲ +6.6%on this news
IM Cannabis to Report Fourth Quarter and Full Year 2024 Financial Results on Monday, March 31 2025 at 9:00am ET
IM Cannabis Corp. is set to report its fourth quarter and full year 2024 financial results on March 31, 2025, prior to market opening. The announcement includes a web conference for investors at 9:00 a.m. ET, providing an opportunity for a Q&A session. IMC operates in key markets such as Israel and Germany, focusing on sustainable growth and compliance within the regulated cannabis industry. The company's commitment to transparency and investor engagement is evident in its forthcoming report and conference call.
Read more →-IMCC
Jan 17, 2025IM Cannabis Announces Change of Auditors
IM Cannabis Corp. has announced a change of auditors from Kost Forer Gabbay & Kasierer to Fahn Kanne & Co. Grant Thornton Israel, effective January 16, 2025. The transition was initiated at the Company's request, with the new auditor appointed upon the audit committee's recommendation. There were no reportable events or reservations in the previous auditor's reports. This change aligns with the company's ongoing focus on governance and compliance in its operations within the medical cannabis sector in Israel and Germany.
Read more →-IMCC
Nov 14, 2024IM Cannabis Reports Third Quarter Financial Results
IM Cannabis Corp. (IMCC) reported its financial results for Q3 2024, marking a 12% increase in revenue to $13.9 million, attributed mainly to significant growth in the German market. The company's operating expenses decreased by 16% to $4.1 million, resulting in an improved operational efficiency ratio. Despite these positive financial indicators, the company faced a net loss of $1.1 million and a decline in total assets by 8.6% compared to the end of 2023. Management emphasizes that their focus on building a strong foundation is geared towards improved performance in 2025.
Read more →Older news (116)
- IM Cannabis Closes Non-Brokered Private Placement led by Management and Concurrent Debt SettlementNov 12, 2024
- IM Cannabis to Report Third Quarter 2024 Financial Results on Thursday, November 14th at 9:00am ETNov 6, 2024
- IM Cannabis Announces up to US$1,613,000 Private Placement Offering Led by ManagementOct 4, 2024
- IMC Germany Announces Outstanding Preliminary Q3, 2024 Performance with 50% Growth Over Q2Oct 2, 2024
- IM Cannabis Announces Appointment of Shmulik Arbel to Board of DirectorsSep 11, 2024
- IM Cannabis Reports Second Quarter Financial ResultsAug 14, 2024
- IM Cannabis to Report Second Quarter 2024 Financial Results on Wednesday, August 14th at 9:00am ETAug 6, 2024
- IM Cannabis Receives NASDAQ Notification of Regaining Compliance with NasdaqJul 29, 2024
- IM Cannabis Shares Commence Trading on 6:1 Consolidated BasisJul 12, 2024
- IM Cannabis Announces Intention to Complete ConsolidationJul 5, 2024
- IMCC Addresses Accelerated Growth in Germany Through new Supply Agreement with EU-GMP Certified Glasshouse Botanics and Announces a Change to its Board of DirectorsJun 5, 2024
- IM Cannabis Closes Convertible Debenture Offering to Support Accelerated Growth in GermanyMay 29, 2024
- IMC announces the termination of a preliminary term sheet with Kadimastem Ltd., a public company traded on the Tel Aviv Stock Exchange to fully focus on the recently legalized German marketMay 28, 2024
- IM Cannabis to Report First Quarter 2024 Financial Results on Wednesday, May 8th at 9:00am ETMay 1, 2024
- IMC to transfer its Oranim Pharmacy shares back to the sellerApr 16, 2024
- Avant and IMC Execute BLK MKT™ Trademark Licensing Agreement for the German Medical Cannabis MarketApr 4, 2024
- IMC applauds the April 1st implementation of the new Israeli cannabis regulation, facilitating access for many new patientsApr 1, 2024
- IM Cannabis Reports 2023 Financial ResultsMar 28, 2024
- IMC Expects Accelerated Growth in Germany from the CountryMar 25, 2024
- IM Cannabis to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 28 at 9:00am ETMar 20, 2024
- IMC Announces Potential Reverse Merger with Kadimastem a leading Clinical cell therapy companyFeb 28, 2024
- IM Cannabis Receives 180 Calendar Day Extension from the Nasdaq Stock Market to Regain Compliance with Bid Price RuleJan 31, 2024
- IMC Reschedules the Final Payment of the Oranim Pharmacy AcquisitionJan 12, 2024
- IMC Announces the Conclusion of the Planning and Construction Legal ProceedingsJan 2, 2024
- New Israeli cannabis regulation, facilitating access for many new patients, scheduled for December 29, 2023, has been postponed by three months; Israeli Ministry of Health published a new report showing a surge in new medical cannabis patients in November 2023Dec 8, 2023
- IM Cannabis Announces Receipt of Court ActionNov 27, 2023
- IM Cannabis Reports Third Quarter 2023 Financial ResultsNov 13, 2023
- IM Cannabis to Report Third Quarter 2023 Financial Results on Monday, November 13 at 9:00am ETNov 8, 2023
- IM Cannabis Releases a Message from the CEO about the Israel-Hamas War and announces securing C$1,390,000 in Short-Term DebtOct 13, 2023
- IM Cannabis Announces the appointment of Uri Birenberg as Chief Financial OfficerOct 10, 2023
- IM Cannabis Announces CFO DepartureSep 19, 2023
- IMC welcomes new Israeli cannabis regulations which are about to change significantly, facilitating access for many new patientsAug 11, 2023
- IM Cannabis to Report Second Quarter 2023 Financial Results on Monday, August 14 at 9:00am ETAug 8, 2023
- IM Cannabis Receives NASDAQ Notification Regarding Minimum Bid Price DeficiencyAug 4, 2023
- IM Cannabis Reports First Quarter 2023 Financial Results; Gross Profit Increased 46% Year-over-YearMay 15, 2023
- IM Cannabis to Report First Quarter 2023 Financial Results on Monday, May 15 at 9:00am ETMay 8, 2023
- IM Cannabis Completes Debt Settlement with L5 CapitalMay 8, 2023
- IM Cannabis Announces Units for Debt SettlementApr 28, 2023
- IM Cannabis to Report Fourth Quarter & Full Year 2022 Financial Results on Wednesday, March 29 at 9:00am ETMar 15, 2023
- IM Cannabis Announces Additional Restructuring Initiatives Designed to Drive Sustainable Profitability and Reduce CostsMar 8, 2023
- IM Cannabis Closes Additional Tranche of LIFE OfferingFeb 16, 2023
- IM Cannabis Provides an Update on Panaxia TransactionFeb 13, 2023
- IM Cannabis Closes Additional Tranches of Private Placement OfferingsFeb 7, 2023
- IM Cannabis Closes Third Tranche of LIFE OfferingJan 31, 2023
- IM Cannabis Closes Second Tranche of Private Placement OfferingsJan 20, 2023
- OREN SHUSTER ACQUIRES SECURITIES OF IM CANNABIS CORP.Jan 17, 2023
- RAFAEL GABAY ACQUIRES SECURITIES OF IM CANNABIS CORP.Jan 17, 2023
- IM Cannabis Common Shares Commence Trading on Consolidated Basis After 1 for 10 Reverse Stock SplitNov 17, 2022
- IM Cannabis Reports Third Quarter 2022 Financial Results; Revenues Increased 78% YoY and 12% SequentiallyNov 14, 2022
- Filed by newsfilecorp.com NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES IM Cannabis Announces USD$5,000,000 Private Placement Toronto, Ontario and Glil Yam, IsraelOct 11, 2022
- IM Cannabis Closes Second Tranche of Non-Brokered Private Placement of Common SharesOct 6, 2022
- Filed by newsfilecorp.com IM Cannabis Closes Second Tranche of Non-Brokered Private Placement of Common Shares Marc Lustig, Executive Chairman of the Company Subscribes for 1,112,504 common shares at USD$0.50 TORONTO andOct 5, 2022
- Filed by newsfilecorp.com DateSep 12, 2022
- RAFAEL GABAY ACQUIRES COMMON SHARES OF IM CANNABIS CORP.Sep 8, 2022
- Filed by newsfilecorp.com NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES IM Cannabis Closes First Tranche of Non-Brokered Private Placement of Common Shares Toronto, OntAug 24, 2022
- Filed by newsfilecorp.com FORM 6 CERTIFICATE OF COMPLIANCE TO: CANADIAN SECURITIES EXCHANGE ("CSE") IM Cannabis Corp. (the "Listed Issuer") hereby certifies to CSE that the Issuer is in compliance with the requirements oAug 22, 2022
- IM Cannabis Reports Record Second Quarter 2022 Financial Results; Revenues Increase 114% YoY to $23.8 MillionAug 15, 2022
- Filed by newsfilecorp.com 510 Burrard St, 3rd Floor Vancouver BC, V6C 3B9Aug 12, 2022
- IM Cannabis to Report Second Quarter 2022 Financial Results on Monday, August 15 at 9:00am ETAug 4, 2022
- IM Cannabis Reports Record First Quarter 2022 Financial Results; Revenues Increase 169% YoY to $23.6 MillionMay 12, 2022
- IM Cannabis to Report First Quarter 2022 Financial Results on Thursday, May 12 at 5:00 p.m. ETMay 5, 2022
- OREN SHUSTER ACQUIRES COMMON SHARES OF IM CANNABIS CORP.Apr 12, 2022
- IM Cannabis Strengthens Focus on Importing Premium and Ultra-Premium Products from its Canadian SubsidiariesApr 6, 2022
- IM Cannabis Reports Record Fourth Quarter and Fiscal Year 2021 Financial Results and Provides First Quarter 2022 OutlookMar 31, 2022
- IM Cannabis Closes Previously Announced Acquisition of Oranim Pharm, JerusalemMar 30, 2022
- IM Cannabis Reschedules Fourth Quarter and Full Year 2021 Conference Call to Thursday, March 31 at 9:00 a.m. ETMar 29, 2022
- IM Cannabis to Report Fourth Quarter and Full Year 2021 Financial Results on Wednesday, March 30 at 9:00 a.m. ETMar 23, 2022
- IM Cannabis Closes Three Previously Announced Strategic Acquisitions in IsraelMar 15, 2022
- IM Cannabis Reports Record Preliminary Fourth Quarter and Full Year 2021 Financial ResultsMar 10, 2022
- IM Cannabis Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communications ProgramFeb 8, 2022
- IM Cannabis announces Focus Medical's Import of 400 Kilograms of Premium-Indoor-Grown Dried Cannabis from Canada to Israel The successful import demonstrates the strength of the IM Cannabis global supply chain and busineJan 19, 2022
- IM Cannabis Corp. Appoints Rinat Efrima as New Chief Executive Officer of IMC Holdings, the Company's Israeli Subsidiary Oren Shuster remains Chief Executive Officer and Director of IM Cannabis Corp.; other managerial chJan 13, 2022
- Filed by newsfilecorp.com FORM 7 MONTHLY PROGRESS REPORT Name of Listed Issuer: IM Cannabis Corp. (the "Issuer" or "IMC"). Trading Symbol: IMCC Number of Outstanding Listed Securities as of 31/12/2021: 68,217,894 Common Jan 10, 2022
- Filed by newsfilecorp.com FORM 11 NOTICE OF PROPOSED STOCK OPTION GRANT OR AMENDMENT Name of Listed Issuer: IM Cannabis Corp. (the "Issuer"). Trading Symbol: IMCC DateDec 30, 2021
- Filed by newsfilecorp.com FORM 7 MONTHLY PROGRESS REPORT Name of Listed Issuer: IM Cannabis Corp. (the "Issuer" or "IMC"). Trading Symbol: IMCC Number of Outstanding Listed Securities as of 30/11/2021: 68,184,163 Common Dec 7, 2021
- IM Cannabis to Launch WAGNERS Brand in Germany IM Cannabis expects to export premium, indoor-grown Canadian cannabis in 2022 to the rapidly evolving German medical cannabis market Toronto, Canada; Glil Yam, Israel and BaDec 7, 2021
- Filed by newsfilecorp.com FORM 9 NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF LISTED SECURITIES (or securities convertible or exchangeable into listed securities) Name of Listed Issuer: Symbol(s): IM Cannabis Corp. (the "IDec 1, 2021
- IM Cannabis to Acquire Oranim, Jerusalem's Leading Medical Cannabis Pharmacy Transaction positions IM Cannabis as one of the largest retailers of medical cannabis in Israel; Retail segment combined annualized revenue of Dec 1, 2021
- IM Cannabis announces Focus Medical's Receipt of Israeli Ministry of Health Import Permit; Plans to Launch WAGNERS Brand in Israel IM Cannabis' popular recreational cannabis brand WAGNERS will be available in Israel in 2Nov 29, 2021
- IM CANNABIS CORP. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2021 UNAUDITED IM CANNABIS CORP. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2021 CANADIAN DOLLARS IN Nov 24, 2021
- IM Cannabis Announces Fourth Installment of Shares in Connection with the Panaxia Transaction Toronto, Canada and Glil Yam, Israel – November 18 2021 IM Cannabis Corp . (the “Company” or “IM CNov 23, 2021
- Filed by newsfilecorp.com FORM 9 NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF LISTED SECURITIES (or securities convertible or exchangeable into listed securities) Name of Listed Issuer: Symbol(s): IM Cannabis Corp. (thNov 22, 2021
- IM Cannabis Announces Third Quarter 2021 Financial Results and Provides Outlook and Business Update Q3 2021 revenues of $14.4 million; a 30% increase from Q2 2021 Gross margin improved to 20% from 5.4% in Q2 2021; expectNov 15, 2021
- Filed by newsfilecorp.com FORM 7 MONTHLY PROGRESS REPORT Name of Listed Issuer: IM Cannabis Corp. (the "Issuer" or "IMC"). Trading Symbol: IMCC Number of Outstanding Listed Securities as of 31/10/2021: 67,838,041 Common Nov 5, 2021
- Filed by newsfilecorp.com FORM 9 NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF LISTED SECURITIES (or securities convertible or exchangeable into listed securities 1 ) Name of Listed Issuer: Symbol(s): IM Cannabis Corp. (theOct 20, 2021
- IMC Announces Third Installment of Shares in Connection with the Panaxia Transaction Toronto, Canada and Glil Yam, IsraelOct 20, 2021
- Filed by newsfilecorp.com FORM 7 MONTHLY PROGRESS REPORT Name of Listed Issuer: IM Cannabis Corp. (the "Issuer" or "IMC"). Trading Symbol: IMCC Number of Outstanding Listed Securities as of 30/09/2021: 67,581,944 Common Oct 6, 2021
- Filed by newsfilecorp.com IM CANNABIS CORP. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2021 UNAUDITED IM CANNABIS CORP. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2021 CANAAug 17, 2021
- Filed by newsfilecorp.com FORM 7 MONTHLY PROGRESS REPORT Name of Listed Issuer: IM Cannabis Corp. (the "Issuer" or "IMC"). Trading Symbol: IMCC Number of Outstanding Listed Securities as of 31/07/2021: 67,298,478 Common Aug 9, 2021
- Filed by newsfilecorp.com IMC Announces Results of its Annual General and Special Meeting of Shareholders Toronto, Canada, Glil Yam, IsraelAug 3, 2021
- Filed by newsfilecorp.com IMC Accelerates its Israeli Retail Position through Acquisition of Leading Retailer and Distributor Pharm Yarok and Rosen High Way Strategically located, best in class retailer with approximatelJul 28, 2021
- Filed by newsfilecorp.com IM Cannabis Provides Update on German Operations and Financial Outlook Toronto, Canada; Bad Oldesloe, Germany; and Glil Yam, IsraelJul 23, 2021
- Filed by newsfilecorp.com IM Cannabis Closes Acquisition of MYM Nutraceuticals TORONTO, CANADA, andJul 9, 2021
- Filed by newsfilecorp.com MYM Shareholders Overwhelmingly Approve Plan of Arrangement with IM Cannabis Highland Grow is currently profitable on an EBITDA basis, unlocks margin expansion and is expected to be immediately Jul 9, 2021
- Filed by newsfilecorp.com FORM 7 MONTHLY PROGRESS REPORT Name of Listed Issuer: IM Cannabis Corp. (the "Issuer" or "IMC"). Trading Symbol: IMCC Number of Outstanding Listed Securities as of 30/06/2021: 57,083,034 Common Jul 8, 2021
- Filed by newsfilecorp.com IM CANNABIS CORP. ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON WEDNESDAY, JULY 28, 2021 NOTICE OF ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS AND MANAGEMENT INFORMATIOJul 1, 2021
- Filed by newsfilecorp.com IM Cannabis Proposed Acquisition of MYM Receives Positive Recommendations from Proxy Advisory Firms Glass Lewis and ISS Glass Lewis and Institutional Shareholder Services recommend that MYM sharJun 28, 2021
- Filed by newsfilecorp.com IM Cannabis Clinical Survey Confirms Effectiveness of Proprietary Strains in Alleviating Symptoms of Seven Key Health Conditions Conditions Evaluated Include Oncology, PTSD, Rheumatoid ArthritisJun 17, 2021
- Filed by newsfilecorp.com FORM 5 QUARTERLY LISTING STATEMENT Name of Listed Issuer: IM Cannabis Corp (the "Issuer"). Trading Symbol: IMCC This Quarterly Listing Statement must be posted on or before the day on which the Jun 11, 2021
- Filed by newsfilecorp.com IM Cannabis Announces Supply Agreement with Canadian LP The Flowr Corporation; Plan to Import Ultra-Premium Products as part of Enhanced Portfolio to Meet Growing Israeli Demand Toronto, Canada;Jun 7, 2021
- Filed by newsfilecorp.com IMC Reports First Closing of the Panaxia Acquisition and Provides Update on Canadian Business Activities Launches WAGNERS brand with new cultivars and SKUs MYM shareholder meeting set forJun 2, 2021
- Filed by newsfilecorp.com IM CANNABIS CORP. INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS As ofMay 18, 2021
- Filed by newsfilecorp.com IM Cannabis Announces Closing of US$ 35 Million Equity Financing Toronto, Canada, Glil Yam, IsraelMay 10, 2021
- Filed by newsfilecorp.com IM Cannabis Announces Pricing of Proposed Public Offering of Securities Toronto, Canada, Glil Yam, IsraelMay 5, 2021
- Filed by newsfilecorp.comMay 3, 2021
- Filed by newsfilecorp.com IM Cannabis Acquires Israel's Largest Retail and Online Pharmacy Business from Panaxia, Creating a Vertically Integrated Global Platform for the IMC Brand With Israel's Fast-Paced E-Commerce AdoApr 30, 2021
- Filed by newsfilecorp.com FORM 51-102F4 BUSINESS ACQUISITION REPORT Item 1 - Identity of Company 1.1 - Name and Address of Company This business acquisition report pertains to IM Cannabis Corp. (the " Company "), with a Apr 29, 2021
- Filed by newsfilecorp.com 2020 ANNUAL REPORT IM CANNABIS CORP. CONSOLIDATED FINANCIAL STATEMENTS AS OF DECEMBER 31, 2020 CANADIAN DOLLARS IN THOUSANDS INDEX Page Report of Independent Registered Public Accounting Firm 2 Apr 26, 2021
- Filed by newsfilecorp.com OPTION AGREEMENT This Option Agreement (the " Agreement ") is made and entered into as of April 2 nd 2019 (the " Effective Date "), by and among I.M.C Holdings Ltd. , a company duly incorporatedApr 2, 2021
- Filed by newsfilecorp.com FORM 9 NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF LISTED SECURITIES (or securities convertible or exchangeable into listed securities 1 ) Name of Listed Issuer: Symbol(s): DateApr 1, 2021
- Filed by newsfilecorp.com FORM 51-102F3 MATERIAL CHANGE REPORT Item 1. - Name and Address of Company IM Cannabis Corp. (the " Company ") 550 Burrard St. #2300 Vancouver, BC, V6C 2B5 Item 2. - Date of Material ChangeMar 31, 2021
- Filed by newsfilecorp.com IMC Closes Acquisition of Trichome, Establishing Global Growth Platform in Both Adult Use and Medical Cannabis Markets TORONTO, ON andMar 18, 2021
- Filed by newsfilecorp.com FORM 51-102F3 MATERIAL CHANGE REPORT Item 1 - Name and Address of Company IM Cannabis Corp. (the " Company ") 550 Burrard St. #2300 Vancouver, BC, V6C 2B5 Item 2 - Date of Material ChangeMar 18, 2021
- Filed by newsfilecorp.com SECOND AMENDING AGREEMENT THIS SECOND AMENDING AGREEMENT (the " Second Amending Agreement ") is made as ofMar 14, 2021
- Filed by newsfilecorp.com IMC Announces Filing of Preliminary Short Form Base Shelf Prospectus Toronto, Canada; Glil Yam, IsraelMar 12, 2021
- Filed by newsfilecorp.com SUPPLEMENTAL WARRANT INDENTURE THIS SECOND SUPPLEMENTAL WARRANT INDENTURE dated as of the 12th day of February, 2021, to the Warrant Indenture made as ofMar 9, 2021
Competitive Position
How IMCC ranks across every disease it competes inCompetitive Position is a premium feature
See how IMCC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial